Synlogic Publishes Preclinical Data Supporting Development of SYNB1618, a Synthetic Biotic™ Medicine as a Potential Treatment for Phenylketonuria
Synlogic, Inc., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, announced the publication of data from preclinical studies of SYNB1618, the Company’s Synthetic Biotic development program targeting PKU, […]